Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawren VandeVrede

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentLawren VandeVrede
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 31, 2024
Clinical use of biomarkers in the era of Alzheimer's disease treatmentsLawren VandeVrede, Suzanne E Schindler
JAMA Neurology|July 28, 2024
Blood-Based Biomarkers for Alzheimer Disease-Ready for Primary Care?Lawren VandeVrede, Gil D Rabinovici
Neuroscience Letters|May 8, 2020
Targeting tau: Clinical trials and novel therapeutic approachesLawren VandeVrede, Adam L Boxer, Manuela Polydoro
Neurology|October 22, 2016
Dizziness caused by meningocele-associated intracranial hypotension in neurofibromatosis type 1Lawren VandeVrede, Rene A Colorado, Jong Woo Lee
The Journal of Clinical Investigation|June 15, 2023
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenuesNiyatee Samudra, Courtney Lane-Donovan, Lawren VandeVrede, et al.
Journal of Medicinal Chemistry|March 21, 2012
Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agentsIsaac T Schiefer, Lawren VandeVrede, Mauro Fa', et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 18, 2020
Four-Repeat Tauopathies: Current Management and Future TreatmentsLawren VandeVrede, Peter A Ljubenkov, Julio C Rojas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentRebecca Snell, Brad F Boeve, Howard J Rosen, et al.
British Journal of Pharmacology|October 15, 2013
Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiationLawren Vandevrede, Ehsan Tavassoli, Jia Luo, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentLawren VandeVrede
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 31, 2024
Clinical use of biomarkers in the era of Alzheimer's disease treatmentsLawren VandeVrede, Suzanne E Schindler
JAMA Neurology|July 28, 2024
Blood-Based Biomarkers for Alzheimer Disease-Ready for Primary Care?Lawren VandeVrede, Gil D Rabinovici
Neuroscience Letters|May 8, 2020
Targeting tau: Clinical trials and novel therapeutic approachesLawren VandeVrede, Adam L Boxer, Manuela Polydoro
Neurology|October 22, 2016
Dizziness caused by meningocele-associated intracranial hypotension in neurofibromatosis type 1Lawren VandeVrede, Rene A Colorado, Jong Woo Lee
The Journal of Clinical Investigation|June 15, 2023
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenuesNiyatee Samudra, Courtney Lane-Donovan, Lawren VandeVrede, et al.
Journal of Medicinal Chemistry|March 21, 2012
Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agentsIsaac T Schiefer, Lawren VandeVrede, Mauro Fa', et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 18, 2020
Four-Repeat Tauopathies: Current Management and Future TreatmentsLawren VandeVrede, Peter A Ljubenkov, Julio C Rojas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentRebecca Snell, Brad F Boeve, Howard J Rosen, et al.
British Journal of Pharmacology|October 15, 2013
Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiationLawren Vandevrede, Ehsan Tavassoli, Jia Luo, et al.
Pageof 8